OneMedNet Enters Its 12th Channel Partner Agreement With A Global Pharmaceutical Intelligence And Data Solutions Provider To Distribute Its Clinical Data; Terms Not Disclosed

The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach US$7.1 billion by 2033, according to Coherent Market Insights1, as pharmaceutical companies increasingly rely on Real-World Data to support drug development, regulatory submissions, and commercial decisions.

OneMedNet is witnessing data partners increasingly select its Real-World Data for the qualities pharmaceutical customers value most: first-party data sourced directly from healthcare providers rather than intermediaries or secondary markets, de-identified at the source, and delivered at regulatory-grade quality. By pairing OneMedNet’s multimodal clinical data with their own analytics and intelligence offerings, partners can support their pharmaceutical customers across clinical development, regulatory submissions, market access, and medical AI.

This agreement marks OneMedNet’s 12th channel partnership, reflecting a deliberate strategy to extend the Company’s commercial reach through established distribution channels while maintaining direct control of data sourcing, curation, and de-identification.